Welcome to Episurf's 4th newsletter!
 ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 
Welcome to Episurf's 4th newsletter!
Welcome to our quarterly newsletter!
 
 
After a wonderful summer, October has already arrived and we have exciting news coming up. In this newsletter,  you can read about our latest product, Epioscopy®, which received CE-mark two weeks ago. Epioscopy® converts MR images to 3D animations enabling easy identification of defects on the menisci, cruciate ligaments and of course chondral and osteochondral defects.

After the great response from our Masterclass we had in June this year, we have already planned for the next Masterclass which will take place in Stockholm in June 2019.

I hope you find our updates interesting and are able to spend some minutes to read about our latest news.

Pål Ryfors, CEO Episurf Medical
 
We are happy to announce the 3rd edition of the Episealer® Masterclass  
 

Join us on 13-14 June 2019 in central Stockholm to interact with a distinguished faculty, to understand more about our Episealer technology and how this is changing the lives of cartilage patients today. Through interactions with orthopaedic peers and engineering professionals, Episurf will guide you through a unique experience, enabling you to understand more about how our technology can offer hope in treating chondral and osteochondral defects.

For more information and registration, contact your local Episurf representative.

Image: Henrik Trygg/mediabank.visitstockholm.com
 
Clinical Update
 
 


Clinical outcome for Episealer presented at the annual meeting of the European Orthopaedic Research Society (EORS) in Galway, Ireland
 
Ass. Prof. Tim Spalding (University Hospitals Coventry and Warwickshire, UK) presented his poster with the results from the international multicentre study on Episealer at the annual meeting of the EORS in  September 2018.

Ass. Prof. Spalding concludes that the study shows excellent early clinical results in the treatment of focal full thickness symptomatic lesions on femoral condyles or the trochlea area of the knee. 

Click here to view a larger version of the poster.
Episealer, a Patient-Specific Implant for Focal Cartilage Lesions - a 24-month follow- up
 
Ass. Prof. Karl Eriksson (Södersjukhuset, Stockholm) presented the latest interim update of the ongoing European multicentre study at the annual meeting of the Swedish Orthopaedic Society (SOF), August 2018.
 
Data presented at Swedish Orthopaedic Society Annual Meeting, August 2018. Title: Episealer, a patient-specific implant for focal cartilage lesions.
  • n=65 at 12 months’ follow-up (n=35 at 24 months)
  • Average age at surgery: 48 years (range 27-67)
  • Medial condyle: 52 - lateral condyle: 5 - trochlea: 8
 
Dr. med. Michael Schramm, Erlangen, Germany
My experience of Episealer
 
 
-Dr Schramm, you performed your first Episealer surgery 24 months ago, what convinced you to start using Episealer?
I had discovered the option of the Episealer procedure at the German orthopaedic convention in Berlin in October 2015 and I was very interested in this kind of treatment. In the former years, I had performed a lot of studies in the laboratory for biomechanical research at the FAU-Erlangen University. This is why I am still fascinated by innovative and rationally new methods for biomechanical repair of cartilage defects. What attracted me the most was the individual design matching the anatomic surface.
I do have a very good experience using such technologies with total knee procedures. I also believe in the function of the hydroxyapatite- covered surface bonding to the bone and the cementless press-fit application.


-What made you decide to use Episealer for your first patients?
In June 2016 I got a special patient referred for arthroscopic treatment. A 66-year old woman with an isolated osteochondral lesion at the medial femoral condyle and the tibial surface was intact. I performed arthroscopy with microfracturing of the damaged area.

She was still in pain following the arthroscopy with microfracturing, she still suffered from effusions of the joint. She obviously needed treatment, but not yet a total knee or a hemiarthroplasty as the tibia was not affected by chondral lesions, also the lateral side and the ligaments were intact.  In her case, the origin of the defect was most likely vascular, like an Ahlbäck disease, but not as big and spread as you would usually expect. There was a treatment gap. 

I considered the case ideal for the Episealer procedure. So I started to get into close contact with the experts for it. I performed the requested special MRI and discussed the case with Prof Leif Ryd from Sweden. The MRI findings with an osteochondral defect, isolated at the distal medial femur, an Episealer could cover her cartilage defect well and it filled the treatment gap. Therefore it was my treatment of choice.


-How is the patient doing today, 24 months after the surgery?
She reports nearly no pain at her operated knee, the VAS Score is rated 1- 2. She is not limited considering walking distance or walking time. She uses no crutches or braces and has a slim joint line without effusions. ADL activities are not compromised. The radiographs demonstrate a very good position of the twin implant, no loosening, no radiographic evidence of progression of the osteoarthrosis.

-With the existing experience of 4 procedures, how does Episealer suit your practice?
The Episealer fits very well into my portfolio of surgeries. It is filling a treatment gap. Up to now four successful cases have convinced me a lot of the usefulness of this individually shaped device. All of those four patients stopped suffering from the typical pain originating from the osteochondral lesions immediately after surgery. I am looking forward to my next upcoming cases!
 
Product Update
 

Epioscopy, our latest product, has arrived! Based on MR images of the patient's knee, an interactive report is created, including a 3D visualisation. Epioscopy enables easy identification of defects on the cruciate ligaments and menisci as well as chondral lesions and bone defects. The product has been developed upon request from our customers who found Episurf's Damage Marking Report very useful and asked if we could further develop the report and visualise the structures which are usually surveyed at an arthroscopy.
 
Upcoming events
 

Episurf endeavours to be present at regional, national and international meetings. For a complete overview of the meetings we are attending, have a look at: http://episurf.com/healthcare-professionals/conferences/.

Some of the highlights:
  • Orthopaedic Knee Conference
    2 November 2018 (Royal Armouries,
    Leeds, UK) 
  • Unicompartmental Knee Meeting
    6 November 2018 (Ashton Gate Stadium, Bristol, UK)
  • Wexham Park Meeting
    15-16 November 2018 (Ascot Conference Centre, Ascot, UK)
  • German Knee Association (DKG)
    23-24 November 2018 (Holiday Inn City Centre, Munich, Germany)
 
In line with the European General Data Protection Regulation (GDPR), Episurf Medical has updated its Privacy Policy. To read our policy, please click on the link below.

If you no longer wish to receive our newsletter, please click the 'unsubscribe' link at the bottom of this newsletter.